Australia markets closed

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.35-0.32 (-3.31%)
At close: 1:00PM EST
8.85 -0.50 (-5.35%)
After hours: 04:25PM EST
Full screen
Trade prices are not sourced from all markets
Previous close9.67
Bid9.14 x 1300
Ask9.60 x 3000
Day's range9.02 - 9.95
52-week range5.41 - 29.90
Avg. volume1,854,811
Market cap858.77M
Beta (5Y monthly)3.62
PE ratio (TTM)N/A
EPS (TTM)-0.37
Earnings date10 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.13
  • Business Wire

    Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

    CAMBRIDGE, Mass., November 24, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will take place November 29 – December 2, 2021. The fireside chat will be available for on-demand viewing on the Seres website.

  • Motley Fool

    Why Shares of Seres Therapeutics Are Up More Than 22% Wednesday

    The company's revenue was $126.7 million, compared with only $1.4 million year over year, with most of the increase from collaboration revenue from Seres' co-commercialization license agreement with NestlΓ© Health Science. The improved financial numbers were only part of the story. On Wednesday, Seres said it had established a collaboration with Swiss pharmaceutical company Bacthera to manufacture SER-109, Seres' lead therapy to treat recurrent Clostridioides difficle infection (rCDI).

  • Zacks

    Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates

    Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 253.19% and 1681.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?